TRAIL signaling has been studied in the context of malignancies, such as melanoma [51], cervical cancer, lung carcinoma [52], breast cancer [53], cholangiocarcinoma [54], leukemia [55], and colorectal cancer [56]. Here, TNFSF10 is linked to melanoma.